Welcome to our dedicated page for Aura Biosciences SEC filings (Ticker: AURA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page compiles U.S. Securities and Exchange Commission (SEC) filings for Aura Biosciences, Inc. (NASDAQ: AURA), a Boston-based clinical-stage biotechnology company developing precision therapies for solid tumors that aim to preserve organ function. These regulatory documents provide detailed insight into AURA’s financial condition, clinical development plans, governance, and capital markets activity.
Among the most frequently referenced filings are Aura’s Form 10-K annual reports and Form 10-Q quarterly reports, which describe the company’s business, risk factors, research and development focus on bel-sar (AU-011), and operating expenses tied to its global Phase 3 CoMpass trial in early or early-stage choroidal melanoma, additional ocular oncology programs, and non-muscle invasive bladder cancer. Investors can also review Form 8-K current reports, such as those filed on dates when Aura announces quarterly results or updates its corporate presentation, to see how the company communicates material events and financial updates.
For users interested in ownership and governance, SEC filings provide information on matters submitted to stockholder votes, including director elections and auditor ratification, as illustrated by Aura’s Form 8-K reporting results of its annual meeting of stockholders. Registration statements and prospectus supplements related to public offerings of common stock and warrants detail how the company raises capital to fund its clinical programs and general corporate purposes.
Stock Titan’s platform enhances these filings with AI-powered summaries that highlight key points from lengthy reports, helping readers quickly understand clinical priorities, cash runway disclosures, and risk factor discussions without reading every page. Real-time updates from EDGAR ensure new AURA filings appear promptly, while structured access to forms such as 10-K, 10-Q, 8-K, and registration statements allows investors to navigate Aura Biosciences’ regulatory history efficiently.
Aura Biosciences announced its financial results for the quarter ended September 30, 2025, via a press release furnished as Exhibit 99.1. The company also updated its corporate presentation for investor and analyst meetings, filed as Exhibit 99.2. The press release is furnished under Item 2.02, while the presentation is filed under Item 8.01.
The materials include forward-looking statements covering development timelines, regulatory interactions, manufacturing, commercialization plans, market opportunities, and financing needs. The company notes an expected cash runway into the first half of 2027, with outcomes subject to clinical, regulatory, and operational risks described in its risk factor disclosures.
Aura Biosciences (AURA) filed a Form 4 disclosing that its Senior Vice President, Finance sold 896 shares of common stock at $6.35 on 10/29/2025. According to the filing, the sale was made to cover tax withholding obligations arising from the vesting of restricted stock units and was automatic, not at the reporting person’s discretion.
Following the transaction, the officer directly holds 85,662 shares of Aura Biosciences common stock.
Aura Biosciences (AURA) Form 4: President and Chief Executive Officer (also a Director) reported an automatic sale tied to tax withholding from RSU vesting. On 10/29/2025, the reporting person sold 9,049 shares of common stock at $6.35 per share (Transaction Code S).
Following the transaction, beneficial ownership was 474,391 shares held directly and 127,763 shares held indirectly through the Elisabet de los Pinos Revocable Trust U/D/T dated April 8, 2016. The filing notes the sale was executed solely to satisfy tax obligations and not at the reporting person’s discretion.
Aura Biosciences (AURA) reported an insider transaction by its Chief Technology Officer. On 10/16/2025, the officer sold 12,169 shares of common stock at $6.35 per share. Following the sale, the officer directly held 197,287 shares.
The filing states the sale was executed to cover tax withholding obligations upon the vesting of restricted stock units and was automatic, not at the officer’s discretion.
Aura Biosciences insider filing reports option exercises and a partial sale to cover costs. On 08/18/2025 Senior Vice President, Finance Amy Elazzouzi exercised long-held options to purchase 12,899 shares of Aura common stock across multiple option tranches and exercise prices. Of those shares, 7,722 were sold in multiple transactions at prices ranging from $6.57 to $6.80 (weighted average reported as $6.70). Following the transactions the reporting person beneficially owns 86,558 shares and holds no remaining derivative securities from the exercised options. The filing states the specific exercise prices and vesting/exercise dates for each option tranche.
AURA Form 144 notice reports a proposed sale of 7,722 common shares acquired by stock option exercise on 08/18/2025. The sale is to be executed through Morgan Stanley Smith Barney LLC on the NASDAQ with an aggregate market value of $51,750.53 based on the filing. The filing states there were 62,119,873 shares outstanding at the time. No other securities were reported sold in the prior three months and payment for the acquired shares was in cash.
Aura Biosciences, Inc. is the issuer covered by this Schedule 13G/A filed by multiple Frazier Life Sciences entities and individuals. The filing shows that Frazier Life Sciences Public Fund, L.P. directly holds 3,113,550 shares of Aura common stock, reported as 5.0% of the class based on the issuer's reported outstanding share counts used in the filing.
The statement also discloses additional direct holdings across related Frazier vehicles: 918,510 shares by the Public Overage Fund, 128,520 by FLS X, 342,210 by FLS XI and 597,210 by FLS XII. Several prefunded warrants are listed (for example, 778,388 warrants held by FLSPF), each subject to a 9.99% beneficial ownership exercise limit. The filing corrects prior attributions to certain investment-committee members and clarifies which entities directly hold the securities.
Aura Biosciences disclosure: Suvretta Capital Management, LLC, Averill Master Fund, Ltd. and Aaron Cowen report shared beneficial ownership positions in Aura Biosciences common stock. Suvretta and Aaron Cowen each report 4,701,775 shares (7.6% of the class); Averill Master Fund reports 4,137,797 shares (6.6% of the class). Each reporting person states no sole voting or dispositive power and reports shared voting and dispositive power for the stated shares. The filing describes pre-funded warrants exercisable subject to a Maximum Percentage cap of 9.99%, which may be increased to up to 19.99% with written notice effective after 61 days; as a result, not all warrants are presently exercisable and the number of shares issuable upon exercise may change with changes in outstanding common stock. The securities reported are directly owned by advisory clients of Suvretta, and the reporting persons disclaim beneficial ownership except to the extent of their pecuniary interest.
Aura Biosciences is a clinical-stage biotech developing Virus-Like Drug Conjugates; its lead candidate bel-sar is in a global Phase 3 CoMpass trial for early choroidal melanoma and in trials for choroidal metastases and bladder cancer. In a Phase 2 cohort of Phase 3-eligible patients, bel-sar achieved an 80% tumor control rate (8 of 10) and 90% visual acuity preservation, with a favorable safety profile; the company reported positive Phase 1 NMIBC data in March 2025 and is advancing a Phase 1b/2 NMIBC program.
On the balance sheet, Aura held $107.4M cash and $69.9M marketable securities (total $177.3M) as of June 30, 2025, received $69.9M net proceeds from a May 16, 2025 follow-on offering, and stated this funding is expected to support operations into the first half of 2027. The company reported a $54.5M net loss for the six months ended June 30, 2025 and an accumulated deficit of $428.7M, reflecting continued high R&D investment.
Aura Biosciences (AURA) furnished a press release announcing its financial results for the quarter ended June 30, 2025 and filed an updated corporate presentation as Exhibit 99.2. The press release is furnished and explicitly not deemed "filed" for purposes of Section 18 of the Exchange Act; the corporate presentation is filed for purposes of Section 18. The company identifies itself as an emerging growth company and notes its common stock trades on The Nasdaq Global Market.
The filing includes a broad cautionary statement of forward-looking items, covering R&D timing and costs, preclinical and clinical trials, manufacturing, third-party collaborations, commercialization, funding and regulatory approvals, market size, and an expected cash runway into the first half of 2027.